Company: SRPT
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001193125-25-044088
Chunk: 3

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 3
---
 their names, and any applicable purchase price,
fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections entitled “Plan of Distribution” and
“About This Prospectus” for more information. The price to the public of those securities and the net proceeds we or any selling securityholders expect to receive from that sale will also be set forth in a prospectus supplement. No
securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such series of securities.

The date of this Prospectus is March 3, 2025.

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                         |     |    i |
| THE COMPANY                                   |     |    1 |
| RISK FACTORS                                  |     |    2 |
| FORWARD-LOOKING STATEMENTS                    |     |    2 |
| USE OF PROCEEDS                               |     |    2 |
| SELLING SECURITYHOLDERS                       |     |    4 |
| GENERAL DESCRIPTION OF SECURITIES WE MAY SELL |     |    5 |
| PLAN OF DISTRIBUTION                          |     |   20 |
| LEGAL MATTERS                                 |     |   23 |
| EXPERTS                                       |     |   23 |
| WHERE YOU CAN FIND MORE INFORMATION           |     |   23 |
| INFORMATION INCORPORATED BY REFERENCE         |     |   23 |
| SIGNATURES AND POWERS OF ATTORNEY             |     | II-5 |

ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-3that we filed with the Securities and Exchange Commission (the “Commission”) using a “shelf” registration process. Under this shelf process, we or any selling securityholder may, from time to time, offer or sell any combination of the securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities offered by us or any selling securityholder. Each time we or any selling securityholder sell securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information about the terms of that offering. The prospectus supplement and any related free writing prospectus that we